44. Cost Effectiveness and Clinical Outcomes of Long Acting Lipoglycopeptides Used in Transitions of Care for Deep-Seated Infections

BACKGROUND: Dalbavancin and oritavancin are long-acting lipoglycopeptides (LaLGPs) FDA-approved for one-time only dosing for skin and skin structure infections. The use of these agents in serious, deep-seated infections requiring protracted antibiotic courses is of increasing interest. The purpose o...

Descripción completa

Detalles Bibliográficos
Autores principales: Antosz, Kayla S, Justo, Julie Ann, Al-hasan, Majdi N, Tabor, Benjamin, Kohn, Joseph, Milgrom, Alexander, Lu, Kevin, Brandon Bookstaver, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644188/
http://dx.doi.org/10.1093/ofid/ofab466.246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644188/
http://dx.doi.org/10.1093/ofid/ofab466.246

Ejemplares similares